ArticleOncotarget2016

Antimetabolite TTL-315 selectively kills glucose-deprived cancer cells and enhances responses to cytotoxic chemotherapy in preclinical models of cancer.

James DuHadaway et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.